arrow
E

Edgar Monterroso

AstraZeneca
H指数:17
被引数:1,339

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort

一线(1L)奥希替尼(osi)± 铂类培美曲塞化疗(CTx)用于EGFR突变(EGFRm)晚期非小细胞肺癌(NSCLC):FLAURA2亚洲队列

2024-12-011
PRE
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study

奥希替尼在不可切除的III期表皮生长因子受体突变的非小细胞肺癌的确定性放化疗后: 来自III期LAURA研究的中枢神经系统疗效和远处进展分析

2024-12-012
OAAI
Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): Post-progression outcomes from the phase III LAURA study

奥希替尼在局部晚期不可切除(UR)III期表皮生长因子受体突变(EGFRm)非小细胞肺癌(NSCLC)患者(pts)经根治性化疗放疗(CRT)后的应用:来自III期LAURA研究的进展后结局

2024-12-010
PRE
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis

奥希替尼(osi)在不可切除的III期表皮生长因子受体突变(EGFRm)非小细胞肺癌患者中进行根治性放化疗(CRT)后的治疗:LAURA中国队列分析

2024-09-010
PRE